Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FER | P16591 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317311 | 1.00 | LRRK2 (0.59) | LRRK2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL30892352 | 1.00 | LRRK2 (0.59) | LRRK2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL30892354 | 1.00 | LRRK2 (0.59) | LRRK2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL10625937 | 0.81 | LRRK2 (0.53) | LRRK2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL7745690 | 0.81 | LRRK2 (0.53) | LRRK2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL7740292 | 0.79 | LRRK2 (0.62) | LRRK2GAAMAPTALDH1A1TTR | |
| SCHEMBL14405656 | 0.79 | LRRK2 (0.62) | LRRK2GAAMAPTALDH1A1TTR | |
| SCHEMBL12804786 | 0.79 | LRRK2 (0.67) | LRRK2GAAMAPTALDH1A1TTR | |
| SCHEMBL12971379 | 0.79 | LRRK2 (0.67) | LRRK2GAAMAPTALDH1A1TTR | |
| SCHEMBL12804785 | 0.79 | LRRK2 (0.67) | LRRK2GAAMAPTALDH1A1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| CN-117945979-A | Isatin derivative, preparation method thereof and application thereof in preparation of plant antibacterial drugs | 陕西师范大学 | 2024-04-30 | — | — | CN | disclosed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| EP-0685463-B1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6207836-B1 | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6127544-A | 1-SUBSTITUTED-3-UREIDO-INDOLIN-2-ONES WHICH EXHIBIT SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM; SUCH AS FOR TREATMENT OF PEPTIC ULCERS, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6114536-A | ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES OF DIGESTIVE ORGANS, SUCH AS PEPTIC ULCER, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-09-05 | — | — | US | disclosed |
| US-6031111-A | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-02-29 | — | — | US | disclosed |
| CN-1046268-C | Indolin-2-one derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-11-10 | — | — | CN | disclosed |
| US-5952511-A | EXHIBITS SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTOR WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO GASTRIN RECEPTOR ANTAGONISM AND USEFUL FOR TREATING PEPTIC ULCER, GASTRITIS, REFLUX ESOPHAGITIS AND ZOLLINGER-ELLISON SYNDROME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0685463-A1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | LRRK2 1548/4885SMN1; SMN2 175/4885GAA 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.